Anti-TIGITxPVRIG antibody and its use
Bispecific antibodies targeting TIGIT and PVRIG enhance T cell function, addressing treatment resistance in cancer therapies by blocking inhibitory signals and promoting activation, effectively inhibiting tumor growth.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- WUXI BIOLOGICS IRELAND LIMITED
- Filing Date
- 2024-06-05
- Publication Date
- 2026-06-11
AI Technical Summary
Current cancer treatments using immune checkpoint blockers like anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies face resistance in over 80% of cancer patients, necessitating novel antibodies that can effectively target immune checkpoint molecules to restore T cell function.
Development of bispecific antibodies that bind to both TIGIT and PVRIG, leveraging specific CDR sequences to enhance anti-tumor immune responses by blocking inhibitory signals and promoting activation signals, potentially in combination with other immunomodulators.
The antibodies synergistically enhance anti-tumor responses by modulating T cell function, overcoming treatment resistance and inhibiting tumor cell proliferation, either alone or in combination with other cancer agents.
Smart Images
Figure 1 Figure 2